Drug Trial Radar · NCT07518160
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Apr 21, 2026
Primary completion
Apr 23, 2028
Study completion Apr 23, 2029
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212 in combination with JS111 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who have progressed after prior EGFR-TKI therapy. The study consists of two parts: a dose-escalation phase followed by an expansion phase. Approximately 30 participants will be enrolled. The dose-escalation phase will explore the safety and tolerability of escalating doses of JS212 in combination with a fixed dose of JS111, using a Bayesian optimal interval (BOIN) design. Based on safety and tolerability data, a recommended Phase III dose (RP3D) will be determined. The expansion phase will further evaluate safety and preliminary anti-tumor activity at the selected dose level.
Conditions
- Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Interventions
JS212 for Injection+JS111 capsules (AP-L1898)Drug
JS212 for Injection: JS212 injection was given every 21 days JS111 capsules (AP-L1898) : JS111 160 mg orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: up to 3 years
- RP3DTime frame: up to 3 years
- Safety (AE)Time frame: up to 6 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.